Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05755360
Other study ID # NN9924-7508
Secondary ID U1111-1274-4674
Status Active, not recruiting
Phase
First received
Last updated
Start date February 21, 2023
Est. completion date October 31, 2024

Study information

Verified date May 2024
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of the study is to look at the change in blood sugar levels in people with type 2 diabetes who change their treatment from DPP4i to oral semaglutide. Participant will get oral semaglutide as prescribed by the study doctor. The study will last for about 5-6 months. Participants will be asked to complete two questionnaires. One will be about eating behaviour and the other one will be diabetes related. Participant will complete this questionnaire during the normal scheduled visit with study doctor. Participants will be asked questions about their health and diabetes treatment and lab tests as part of their normal doctor's appointment.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 390
Est. completion date October 31, 2024
Est. primary completion date October 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) - The decision to switch from DPP4i treatment to commercially available oral semaglutide has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the participant in this study - Participant with last measurement of HbA1c >= 7.5% at informed consent and treatment initiation visit (V1) or less than or equal to (<=) 90 days before informed consent and treatment initiation visit (V1) - Treatment naïve to insulin. An exception is short-term insulin treatment for acute illness for a total of < 14 days Exclusion Criteria: - Previous participation in this study. Participation is defined as having given informed consent in this study - Participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days prior to the informed consent and treatment initiation visit (V1) and throughout the duration of the study - Participants with type-1 diabetes - Participants who are pregnant or who become pregnant (or who plan to become pregnant) during the study period - Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. - Age < 18 years on the informed consent and treatment initiation visit (V1)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Semaglutide
Participants will be treated with commercially available oral semaglutide according to routine clinical practice at the discretion of the treating physician. The decision to switch from DPP4i treatment to oral semaglutide is at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.

Locations

Country Name City State
Italy Ospedale Pesenti Fenaroli Alzano Lombardo
Italy INRCA Ancona
Italy A.O.U. Policlinico S.Orsola Bologna
Italy Ospedale centrale L. Bohler Bolzano
Italy ASL Caserta Caserta
Italy Azienda Ospedaliera Cannizzaro Catania
Italy ASL Cuneo 1 Cuneo
Italy Università degli Studi Foggia Foggia
Italy Ospedale Misericordia Grosseto
Italy Ospedale Generale provinciale Macerata
Italy Ospedale Pagliari Massafra
Italy ASL Avellino Montoro
Italy ASL Lecce Nardò
Italy ASL Napoli 3 sud Palma Campania
Italy A.O.U. Maggiore della Carità Piemonte
Italy Ospedale San Jacopo Pistoia
Italy P.O. Praia a Mare Praia a Mare
Italy Casa della Salute ASL RM2 Roma
Italy Fondazione Univ. Policlinico A.Gemelli Roma
Italy Ospedale Santo Spirito Roma
Italy A.O.U. Policlinico Giaccone Sicilia
Italy Casa di cure Triolo Zancla Sicilia
Italy Ospedale Treviglio Treviglio
Italy Ospedale S. Maria della Misericordia Udine
Italy ASST Sette Laghi Varese

Sponsors (1)

Lead Sponsor Collaborator
Novo Nordisk A/S

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Absolute change in glycated haemoglobin (HbA1c) (percentage [%]-point) Measured in %-point. From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)
Primary Absolute change in glycated haemoglobin (HbA1c) (millimoles per mole [mmol/mol]) Measured in mmol/mol. From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)
Secondary Relative change in body weight Measured in percentage (%). From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)
Secondary Absolute change in body weight Measured in Kilograms (kg). From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)
Secondary Absolute change in lipid parameters (total cholesterol, low density lipoprotein cholesterol [LDLc], high density lipoprotein cholesterol [HDLc], triglycerides) Measured in millimoles per liter (mmol/L). From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)
Secondary Absolute change in waist circumference Measured in centimeters (cm). From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)
Secondary Absolute change in blood pressure (systolic and diastolic) Measured in millimeters of mercury (mmHg). From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)
Secondary Number of participants with HbA1c less than (<) 7% Measured as number of participants (yes or no). At end of study (week 40 ± 4 weeks)
Secondary Number of participants with HbA1c <6.5% Measured as number of participants (yes or no). At end of study (week 40 ± 4 weeks)
Secondary HbA1c reduction greater than or equal to (>=) 1%-point and body weight reduction of >= 5% Measured as number of participants (yes or no). From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)
Secondary HbA1c reduction greater than or equal to (>=) 1%-point and body weight reduction of >= 3% Measured as number of participants (yes or no). From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)
Secondary Self-reported severe hypoglycaemia during the study period Measured as number of participants (yes or no). From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)
Secondary Absolute change in dutch eating behaviour questionnaire (DEBQ) scores (points) DEBQ is a 33-item self-reported questionnaire to assess three distinct eating behaviours in adults: emotional eating, external eating, and restrained eating. For all 33 items participants will provide response in terms of: never, seldom, sometimes, often, very often. Absolute change in DEBQ (total score) calculated as the absolute difference between the DEBQ scores (total score) at baseline and post baseline measurements of DEBQ scores (total score) up to and including end of study visit. From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)
Secondary Absolute change in diabetes distress survey (DDS) scores (points) DDS is a self-administered 17-item scale that captures four critical dimensions of diabetes-related distress: emotional burden, regimen distress, interpersonal distress, and physician distress. Each item was scored in the range of 1 to 6: 1) not a problem; 2) a slight problem; 3) a moderate problem; 4) somewhat serious problem; 5) a serious problem; 6) a very serious problem. Participants will rate each item item indicating the degree to which each of the 17 items may have distressed or bothered them during the past month. High score indicated high distress. From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2